Pregabalin is a GABA analogue used to treat neuropathic pain associated with conditions like diabetic neuropathy and post-herpetic neuralgia. It is also used as an adjunctive therapy for epilepsy and fibromyalgia. Pregabalin has higher potency and bioavailability than gabapentin, allowing lower doses to be used. It has distinct pharmacokinetic advantages over gabapentin and provides equivalent efficacy at much lower doses. The maximum recommended dose of pregabalin is 300mg per day.
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPTX, PDF, TXT or read online on Scribd
0 ratings0% found this document useful (0 votes)
305 views9 pages
Ogrania: Pregabalin 75 MG Capsules
Pregabalin is a GABA analogue used to treat neuropathic pain associated with conditions like diabetic neuropathy and post-herpetic neuralgia. It is also used as an adjunctive therapy for epilepsy and fibromyalgia. Pregabalin has higher potency and bioavailability than gabapentin, allowing lower doses to be used. It has distinct pharmacokinetic advantages over gabapentin and provides equivalent efficacy at much lower doses. The maximum recommended dose of pregabalin is 300mg per day.
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPTX, PDF, TXT or read online on Scribd
You are on page 1/ 9
OGRANIA
Pregabalin 75 mg capsules Pregabalin is a GABAergic anticonvulsant and depressant of the central nervous system (CNS). It is classified as a GABA analogue and gabapentinoid.
It is a close analogue of the inhibitory neurotransmitter
γ-aminobutyric acid (GABA). Although pregabalin is an analogue of GABA, it does not bind directly to GABAA, GABAB, GABAϱ, or benzodiazepine receptors. Nor does it block sodium channels and is not active at opioid receptors. Gabapentinoids, such as pregabalin, are α2δ subunit modifiers that affect GABA. In contrast to the distribution of α2δ-1 and α2δ-2 subunits binding correlates partially with GABAergic neurons. INDICATIONS Management of neuropathic pain associated with diabetic peripheral neuropathy. Management of post-herpetic neuralgia.
Adjunctive therapy for adult patients with partial onset
seizures. Management of fibromyalgia.
Management of neuropathic pain associated with spinal
cord injury( ex. Sciatica) POTENCY When studied in non-humans pregabalin appears to be 3 to 10 times more potent as an anticonvulsant than gabapentin. Pregabalin is 2 to 4 times more potent as an analgesic than gabapentin. Pregabalin is 6 times more potent than gabapentin in binding affinity. COMPARISON WITH GABAPENTIN Pregabalin has been shown in studies to provide equivalent efficacy to gabapentin, however, at much lower doses. Because lower dosages can be used to treat neuropathic pain, it is likely that pregabalin will be associated with fewer dose-related adverse events. Part of the reason why pregabalin requires lower dosages is that it has a much higher bioavailability (90% versus 33-66%) and is rapidly absorbed (peak: 1 hr). Also, plasma concentrations increase linearly with increasing dose. This is not true with gabapentin.
Gabapentin is slowly absorbed (peak: 3 to 4 hours post-
dose) and more importantly, plasma concentrations have been found to have a non-linear relationship to increasing doses. Pregabalin has been found to have distinct pharmacokinetic advantages over gabapentin. DOSE Maximum dose in patients with normal creatinine clearance, is 600 mg/day in divided doses, but because of dose related adverse events and no added benefit, doses above 300 mg are not recommended. The usual starting dose is 75 mg once or twice daily and increasing gradually, and when discontinued, tapered gradually over a minimum of 1 week. OGRANIA Target Doctor: Neurologist, Internist, Neurosurgeon, Orthopedist. Dose and indications :mentioned
Message: Ogrania provides as high quality pregabalin,
with a cost-effective course when compared with other competitors in the market.